• Record 1H FY26 revenue of $6.2 million, up 48% on prior period
• Gross profit of $3.0 million, up 63% with gross margin increasing to 55%
• US commercial launch progressing to plan, 45 states approved for Remplir™ sales

Orthocell Ltd, a regenerative medicine company, has reported record half-year financial results for the 6 months ended 31 December 2025. The company achieved revenue of $6.2 million, up 48% on the prior corresponding period, delivering two consecutive record quarters (1Q FY26: $3.0m; 2Q FY26: $3.2m) and a Compound Half-Year Growth Rate (CHGR) of 21% since 2H FY24. Gross profit increased 63% to $3.0 million, with gross margin expanding to 55% driven by operating cost efficiencies and higher-margin Remplir sales. The company's US commercial launch of Remplir™ is progressing to plan, with the product now approved for sale in 45 states (remaining 5 expected by 3Q FY26). The company also secured Canadian national distribution, with first sales expected in 1H CY26, and continued strong performance in Australia, New Zealand and Hong Kong. Orthocell is expanding into nerve-sparing prostate surgery, with growing procedural adoption in Australia, and has submitted EU and UK regulatory applications for Remplir™, targeting entry into an estimated US$750m nerve repair market. The company completed a $30 million capital raise during the period, strengthening its balance sheet with $49.4 million in cash reserves as of 31 December 2025.

Orthocell expects continued revenue growth as US sales scale and recently established international markets contribute more meaningfully through CY26, supported by a well-capitalised balance sheet that provides flexibility to accelerate global expansion.